| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 The Mary Crowley Medical Research Center and the 2 Cancer Immunology Research Laboratory, Baylor-Sammons Cancer Center, 3 Murex Pharmaceuticals, Dallas, Texas; and 4 Institute of Biomedical Studies, Baylor University, Waco, Texas
Requests for reprints: Alex W. Tong, Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, 530 Sammons Tower, 3500 Gaston Avenue, Dallas, TX 75246. Phone: 214-820-4123; Fax: 214-820-2780; E-mail: alext{at}baylorhealth.edu.
Despite successes in animal models, cancer gene therapy with small interfering RNAs (siRNA) is hindered by the lack of an optimal delivery platform. We examined the applicability of the replication-competent, oncolytic adenovirus, ONYX-411, to deliver a mutant K-ras siRNA transgene to human cancer cells. Proof-of-principle studies showed an additive tumor growthinhibitory response through siRNA-mediated K-ras knockdown and ONYX-411-mediated cancer cell lysis. A novel construct, termed Internavec (for interfering RNA vector), was generated by cloning a K-rasv12-specific siRNAras-4 hairpin construct under the control of the human H1 promoter into the deleted E3b region of ONYX-411. Internavec acquired an increase in potency of
10-fold in human cancer cells expressing the relevant K-rasv12 mutation (H79, H441, and SW480), as defined by a reduction in the effective dose needed to achieve 50% growth inhibition (ED50). Internavec remained attenuated in nonmalignant epithelial cells. Daily intratumoral injections of Internavec (five daily injections of 1 x 108 plaque-forming units) significantly reduced the growth of s.c. H79 pancreatic cancer xenografts in nu/nu mice by 85.5%, including complete growth suppression in three of five mice. Parental ONYX-411 or ONYX-411-siRNAGFP was markedly less effective (47.8% growth reduction, P = 0.03; and 44.1% growth reduction, P = 0.03, respectively). siRNAras transgene activity contributed to cell cycle blockage, increased apoptosis, and marked down-regulation of Ras signalingrelated gene expression (AKT2, GSK3ß, E2F2, and MAP4K5). These findings indicate that Internavec can generate a two-pronged attack on tumor cells through oncogene knockdown and viral oncolysis, resulting in a significantly enhanced antitumor outcome. (Cancer Res 2006; 66(19): 9736-43)
This article has been cited by other articles:
![]() |
E. Gurlevik, N. Woller, P. Schache, N. P. Malek, T. C. Wirth, L. Zender, M. P. Manns, S. Kubicka, and F. Kuhnel p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication Nucleic Acids Res., July 1, 2009; 37(12): e84 - e84. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ramakrishna, N. Woller, B. Mundt, S. Knocke, E. Gurlevik, M. Saborowski, N. Malek, M. P. Manns, T. Wirth, F. Kuhnel, et al. Antitumoral Immune Response by Recruitment and Expansion of Dendritic Cells in Tumors Infected with Telomerase-Dependent Oncolytic Viruses Cancer Res., February 15, 2009; 69(4): 1448 - 1458. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Gomes, M. S. Rodrigues, A. P. Phadke, L. D. Butcher, C. Starling, S. Chen, D. Chang, R. Hernandez-Alcoceba, J. T. Newman, M. J. Stone, et al. Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154) Transgene Construct in Human Breast Cancer Cells Clin. Cancer Res., February 15, 2009; 15(4): 1317 - 1325. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. John, O. L. Caballero, S. J. Svobodova, A. Kong, R. Chua, J. Browning, S. Fortunato, S. Deb, M. Hsu, C. A. Gedye, et al. ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non-Small Cell Lung Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3291 - 3298. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |